HCIA
FATE icon

Hochman Cole Investment Advisors’s Fate Therapeutics FATE Stock Holding History

Hochman Cole Investment Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-12,471
Closed -$141K – 109
2018
Q2 		$141K Sell
12,471
-5,093
-29% -$56.1K 0.09% 105
2018
Q1 		$171K Sell
17,564
-16,633
-49% -$159K 0.12% 98
2017
Q4 		$209K Sell
34,197
-5,641
-14% -$25.2K 0.13% 95
2017
Q3 		$158K Buy
+39,838
New +$135K 0.1% 97
2017
Q1 		– Sell
-10,887
Closed -$27K – 89
2016
Q4 		$27K Buy
+10,887
New +$29.1K 0.02% 89
2016
Q3 		– Sell
-11,005
Closed -$19K – 85
2016
Q2 		$19K Sell
11,005
-5,336
-33% -$9.67K 0.02% 76
2016
Q1 		$29K Hold
16,341
– – 0.02% 78
2015
Q4 		$55K Buy
+16,341
New +$68.7K 0.05% 76

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $950M AUM 57.92% 1-Year Est. Return